HUE052299T2 - LFA-1 inhibitor készítmények - Google Patents

LFA-1 inhibitor készítmények

Info

Publication number
HUE052299T2
HUE052299T2 HUE13865757A HUE13865757A HUE052299T2 HU E052299 T2 HUE052299 T2 HU E052299T2 HU E13865757 A HUE13865757 A HU E13865757A HU E13865757 A HUE13865757 A HU E13865757A HU E052299 T2 HUE052299 T2 HU E052299T2
Authority
HU
Hungary
Prior art keywords
lfa
inhibitor compositions
inhibitor
compositions
Prior art date
Application number
HUE13865757A
Other languages
English (en)
Hungarian (hu)
Inventor
Mary Newman
William Hunke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE052299(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE052299T2 publication Critical patent/HUE052299T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HUE13865757A 2012-12-19 2013-12-18 LFA-1 inhibitor készítmények HUE052299T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29

Publications (1)

Publication Number Publication Date
HUE052299T2 true HUE052299T2 (hu) 2021-04-28

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13865757A HUE052299T2 (hu) 2012-12-19 2013-12-18 LFA-1 inhibitor készítmények

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP3827823A1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA028008B1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX391620B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
EP3955926A4 (en) 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
IL302174A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of eye disorders
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
CA2532207A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
US8168655B2 (en) * 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
WO2007007863A1 (en) * 2005-07-08 2007-01-18 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
EP2265124A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
ES2763703T3 (es) 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
CN102548548B (zh) * 2009-06-10 2017-09-01 米拓科技有限公司（卢森堡） 用于医学和兽医学的眼科药物组合物
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
CA2781698A1 (en) * 2009-11-23 2011-05-26 Allergan, Inc. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
BR112013021048A2 (pt) * 2011-02-18 2016-10-18 M S Appasmy Associates composição oftálmica para permitir dilatação de pupilas
JP2014518278A (ja) * 2011-06-29 2014-07-28 アラーガン インコーポレイテッド 蕁麻疹の治療に用いるアルカフタジン
EP2830627B1 (en) * 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
DK2934510T3 (da) 2021-01-25
ZA201608069B (en) 2017-11-29
NZ708821A (en) 2020-03-27
AU2013361579B2 (en) 2018-05-24
EA028008B1 (ru) 2017-09-29
US11058677B2 (en) 2021-07-13
JP6373867B2 (ja) 2018-08-15
ZA201504404B (en) 2020-01-29
CN104955453B (zh) 2018-09-18
HK1214536A1 (zh) 2016-07-29
EP2934510B1 (en) 2020-10-28
MX2019012375A (es) 2020-01-20
PL2934510T3 (pl) 2021-07-05
EA201591180A1 (ru) 2015-12-30
BR112015014367B1 (pt) 2022-11-22
EP3827823A1 (en) 2021-06-02
MX2015007540A (es) 2016-04-13
JP2016503058A (ja) 2016-02-01
EA201791321A1 (ru) 2018-04-30
CN104955453A (zh) 2015-09-30
IL239490B (en) 2018-12-31
CA2894170C (en) 2021-08-10
SI2934510T1 (sl) 2021-02-26
CA2894170A1 (en) 2014-06-26
AU2013361579A1 (en) 2015-06-18
US20150320737A1 (en) 2015-11-12
KR20150100763A (ko) 2015-09-02
EP2934510A1 (en) 2015-10-28
ES2846724T3 (es) 2021-07-29
PT2934510T (pt) 2021-01-13
KR101891144B1 (ko) 2018-08-23
IL239490A0 (en) 2015-08-31
WO2014100135A1 (en) 2014-06-26
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
MX368876B (es) 2019-10-21
US20220000859A1 (en) 2022-01-06
BR112015014367A2 (pt) 2017-07-11
MX391620B (es) 2025-03-19

Similar Documents

Publication Publication Date Title
LT3725778T (lt) Enzalutamido kompozicijos
SI3715345T1 (sl) Priprava zaviralca lfa-1
HUE036259T2 (hu) Inhibitor vegyületek
LT2841428T (lt) Dnr-pk inhibitoriai
LT2791160T (lt) Modifikuotos mrnr sudėtys
HUE040055T2 (hu) RET inhibitor
SMT201600114B (it) Inibitori di beta-secretasi
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
BR112013017183A2 (pt) composições de bepostatina
DK2911506T3 (da) Driftreducerende sammensætninger
HRP20170226T1 (hr) Spoj pirazinkarboksamida
BR112014032798A2 (pt) composição
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
EP2912131A4 (en) Adhesive compositions
BR112015003038A2 (pt) composições lubrificantes
ME03413B (me) Kompozicije које sadrže peg i askorbat
EP2903015A4 (en) BREAKERS
DK2822967T3 (da) Compositions comprising secretory - like immunoglobulins
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
ME02985B (me) Prolekovi inhibitora amino-hinazolinske kinaze
FR2993777B1 (fr) Composition photo-protectrice
SMT201600357B (it) Inibitori di iap
EP2920370A4 (en) POST
BR112014032712A2 (pt) composição
HUE049445T2 (hu) Új kompozíciók